The Impact of Empagliflozin on Obstructive Sleep Apnea and Cardiovascular and Renal Outcomes: An Exploratory Analysis of the EMPA-REG OUTCOME Trial
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To explore the effects of empagliflozin on the incidence of obstructive sleep apnea (OSA) and its effects on metabolic, cardiovascular (CV), and renal outcomes among participants with or without OSA in the EMPA-REG OUTCOME trial. RESEARCH DESIGN AND METHODS: Participants with diabetes and CV disease were randomized to empagliflozin (10 and 25 mg) or placebo daily in addition to standard of care. OSA was assessed by investigator report using Medical Dictionary for Regulatory Activities version 18.0, and CV outcomes were independently adjudicated. Analyses were performed using multivariable-adjusted Cox regression models. RESULTS: OSA was reported in 391 of 7,020 (5.6%) participants at baseline. Those with OSA were more likely to be male (83% vs. 71%) and to have moderate to severe obesity (BMI ≥35 kg/m2; 55% vs. 18%). Over a median of 3.1 years, empagliflozin had similar placebo-adjusted reductions in HbA1c, waist circumference, and systolic blood pressure, regardless of OSA status, but a larger effect on weight (adjusted mean ± SE difference at week 52: OSA vs. no OSA −2.9 ± 0.5 vs. −1.9 ± 0.1 kg). Incidence of 3-point major adverse CV events, CV death, heart failure hospitalization, and incident or worsening nephropathy in the placebo group was 1.2- to 2.0-fold higher for those with baseline OSA compared with those without. Empagliflozin significantly reduced the risk for outcomes regardless of OSA status (P-interaction all >0.05). Fifty patients reported a new diagnosis of OSA through 7 days after medication discontinuation, and this occurred less often with empagliflozin treatment (hazard ratio 0.48 [95% CI 0.27, 0.83]). CONCLUSIONS: In EMPA-REG OUTCOME, participants with OSA had greater comorbidity and higher frequency of CV and renal events. Empagliflozin had favorable effects on risk factors and CV and renal outcomes regardless of preexisting OSA and may also reduce the risk for new-onset OSA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“SGLT2i have been shown to reduce incident obstructive sleep apnea in two SGLT2i CVOTs based on adverse event reporting (304,305).”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationHealth effects of overweight and obesity in 195 countries over 25 years
Collaborators, T. G. 2. O. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614362 · Cited by 7,918
Increased Prevalence of Sleep-Disordered Breathing in Adults
Peppard, P. E., Young, T., Barnet, J. H., Palta, M., Hagen, E. W., & Hla, K. M. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws342 · Cited by 4,618 · cited 1×
“, at 50–70 years, 9% in women and 17% in men) (2).”
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citationObstructive Sleep Apnea as a Risk Factor for Stroke and Death
Yaggi, H. K., Concato, J., Kernan, W. N., Lichtman, J. H., Brass, L. M., & Mohsenin, V. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043104 · Cited by 3,004 · cited 1×
“OSA and type 2 diabetes frequently occur together, and both are associated with adverse metabolic consequences that increase the risk for cardiovascular disease (CVD) (4), including stroke, myocardial infarction, hospitalization for heart failure (HHF), cardiovascular (CV) death, and all-cause mortality (5,6), as well…”
BackgroundSelf-citationThe epidemiology of adult obstructive sleep apnea
Punjabi, N. M. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200709-155mg · Cited by 2,361
Drager, L. F., Togeiro, S. M., Polotsky, V. Y., & Lorenzi-Filho, G. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.045 · Cited by 886
Inzucchi, S. E., Zinman, B., Fitchett, D., Wanner, C., Ferrannini, E., Schumacher, M., Schmoor, C., Ohneberg, K., Johansen, O. E., George, J. T., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1096 · Cited by 740 · cited 1×
“on CV deaths (19) (Supplementary Appendix,”
Self-citationObstructive Sleep Apnea and Diabetes
Reutrakul, S., & Mokhlesi, B. (2017) · Chest · doi:10.1016/j.chest.2017.05.009 · Cited by 667 · cited 1×
“Furthermore, OSA may worsen glucose tolerance, impair diabetes management, and lead to poor glycemic control (8).”
BackgroundObstructive Sleep Apnea in Adults
Veasey, S. C., & Rosen, I. M. (2019) · New England Journal of Medicine · doi:10.1056/nejmcp1816152 · Cited by 615
Cited by
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetes Care · doi:10.2337/dci22-0034 · Cited by 2,104
Ahmad, E., Lim, S., Lamptey, R., Webb, D. R., & Davies, M. J. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01655-5 · Cited by 1,120
Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05787-2 · Cited by 1,048
Gliflozins in the Management of Cardiovascular Disease
Braunwald, E. (2022) · New England Journal of Medicine · doi:10.1056/nejmra2115011 · Cited by 266
Obesity and Obstructive Sleep Apnea
Bonsignore, M. R. (2021) · Handbook of experimental pharmacology · doi:10.1007/164_2021_558 · Cited by 126
Treatment options in obstructive sleep apnea
Gambino, F., Zammuto, M. M., Virzì, A., Conti, G., & Bonsignore, M. R. (2022) · Internal and Emergency Medicine · doi:10.1007/s11739-022-02983-1 · Cited by 103
Current and novel treatment options for obstructive sleep apnoea
Randerath, W. J., de Lange, J., Hedner, J. A., Ho, J. T. F., Marklund, M., Schiza, S., Steier, J. S., & Verbraecken, J. A. (2022) · ERJ Open Research · doi:10.1183/23120541.00126-2022 · Cited by 98
Non-CPAP therapy for obstructive sleep apnoea
Verbraecken, J. A., Dieltjens, M., de Beeck, S. O., Vroegop, A. V. M. T., Braem, M. J. A., Vanderveken, O. M., & Randerath, W. J. (2022) · Breathe · doi:10.1183/20734735.0164-2022 · Cited by 83
Sleep Apnea and Cardiovascular Risk in Patients with Prediabetes and Type 2 Diabetes
Paschou, S. Α., Bletsa, E., Saltiki, K., Kazakou, P., Kantreva, K., Katsaounou, P. A., Rovina, N., Trakada, G., Bakakos, P., Vlachopoulos, C. V., et al. (2022) · Nutrients · doi:10.3390/nu14234989 · Cited by 78
Obesity, Bariatric Surgery and Obstructive Sleep Apnea—A Narrative Literature Review
Wyszomirski, K., Walędziak, M. S., & Różańska-Walędziak, A. M. (2023) · Medicina · doi:10.3390/medicina59071266 · Cited by 62
Young, K., McInnes, E. H., Massey, R. J., Kahkoska, A. R., Pilla, S. J., Raghavan, S., Stanislawski, M. A., Tobias, D. K., McGovern, A. P., Dawed, A. Y., et al. (2023) · Communications Medicine · doi:10.1038/s43856-023-00359-w · Cited by 54
Spallone, V., & Valensi, P. E. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101224 · Cited by 46
Ertugliflozin and incident obstructive sleep apnea: an analysis from the VERTIS CV trial
Wojeck, B. S., Inzucchi, S. E., Neeland, I. J., Mancuso, J. P., Frederich, R., Masiukiewicz, U., Cater, N. B., McGuire, D. K., Cannon, C. P., & Yaggi, H. K. (2023) · Sleep and Breathing · doi:10.1007/s11325-022-02594-2 · Cited by 41
“We found a significant 48% adjusted relative risk reduction that was observed with ertugliflozin versus placebo for incident OSA, similar to the magnitude of effect observed with empagliflozin [9].”
ResultSelf-citationPapaetis, G. S. (2023) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/161170 · Cited by 41
Impact of Visceral and Hepatic Fat on Cardiometabolic Health
Khawaja, T., Nied, M., Wilgor, A., & Neeland, I. J. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02127-1 · Cited by 49
“Lastly, SGLT2 inhibitors have also been found to reduce the incidence of obstructive sleep apnea and have favorable impact on risk factors for cardiovascular outcomes in patients with T2D and ASCVD [64, 65].”
BackgroundSelf-citationHeffernan, A., Duplančić, D., Kumrić, M., Kurir, T. T., & Božić, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063243 · Cited by 39
Natale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 69
Potential Use of SGLT-2 Inhibitors in Obstructive Sleep Apnea: A new treatment on the horizon
Tanrıöver, C., Uçku, D., Akyol, M., Çevik, E., Kanbay, A., Sridhar, V. S., Cherney, D. Z. I., & Kanbay, M. (2022) · Sleep And Breathing · doi:10.1007/s11325-022-02606-1 · Cited by 36
Bugga, P., Mohammed, S. A., Alam, M. J., Katare, P. B., Meghwani, H., Maulik, S. K., Arava, S. K., & Banerjee, S. K. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120862 · Cited by 33
Association between Obstructive Sleep Apnea and Heart Failure in Adults—A Systematic Review
Polecka, A., Olszewska, N., Danielski, Ł., & Olszewska, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12196139 · Cited by 38
“Additionally, an analysis of the EMPA-REG OUTCOME trial revealed that patients with OSA were at increased risk of cardiovascular and kidney events and higher all-cause mortality [43].”
MethodSleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update
Romigi, A., Feola, T., Cappellano, S., De Angelis, M., Pio, G., Caccamo, M., Testa, F., Vitrani, G., Centonze, D., Colonnese, C., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2021.817257 · Cited by 28
Sleep Deficiency and Opioid Use Disorder
Langstengel, J., & Yaggi, H. K. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.05.001 · Cited by 26
Self-citationKasai, T., Kohno, T., Shimizu, W., Ando, S., Joho, S., Osada, N., Kato, M., Kario, K., Shiina, K., Tamura, A., et al. (2024) · Circulation Journal · doi:10.1253/circj.cj-23-0489 · Cited by 28
Self-citationXie, L., Li, S., Yu, X., Qin, W. D., Yu, F., & Tong, J. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03643-3 · Cited by 24
Papaetis, G. S. (2021) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad.2021.105314 · Cited by 25
“A recent exploratory post-hoc analysis of the EMPA-REG OUTCOME trial suggested that approximately 6% of participants had OSAS at baseline, and that patients with OSAS experienced higher overall all-cause mortality, as well as cardiovascular and kidney events, confirming the huge cardiorenal burden that characterize th…”
MethodKarakasis, P., Sagris, Μ., Patoulias, D., Koufakis, T., Theofilis, P., Klisic, A. N., Fragakis, N., El‐Tanani, M., & Rizzo, M. (2024) · Biomedicines · doi:10.3390/biomedicines12112503 · Cited by 24
“In the placebo group, patients with baseline OSA exhibited a 1.2-to 2.0-fold higher incidence of 3-point major adverse cardiovascular events, cardiovascular death, heart failure hospitalization, and worsening nephropathy compared to those without OSA [107].”
InfluentialArmentaro, G., Pelaia, C., Condoleo, V., Severini, G., Crudo, G., Marco, M. D., Pastura, C. A., Tallarico, V., Pezzella, R., Aiello, D., et al. (2024) · Biomedicines · doi:10.3390/biomedicines12050937 · Cited by 22
“Those with OSA may lose more weight with SGLT2 inhibition than those without OSA, according to the secondary analysis of EMPA-REG OUTCOME by Neeland and colleagues [46].”
ResultExpanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 26
“Moreover, SGLT-2 inhibitors mitigate pulmonary hypertension and obstructive sleep apnoea, suggesting broader respiratory advantages [163–165].”
Saeed, S., Romarheim, A., Solheim, E., Bjorvatn, B., & Lehmann, S. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2081547 · Cited by 21
Monda, V. M., Gentile, S., Porcellati, F., Satta, E., Fucili, A., Monesi, M., & Strollo, F. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02310-2 · Cited by 20
Sleep-Disordered Breathing and Hypertension—A Systematic Review
Battisha, A., Kahlon, A., & Kalra, D. K. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14093115 · Cited by 18
“These agents improve glycemic control, induce modest weight loss, and reduce blood pressure, and they significantly lower rates of cardiovascular and renal events in high-risk patients with or without coexisting OSA [101,102].”
Obstructive Sleep Apnea and Type 2 Diabetes: An Update
Gentile, S., Monda, V. M., Guarino, G., Satta, E., Chiarello, M., Caccavale, G., Mattera, E., Marfella, R., & Strollo, F. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155574 · Cited by 24
“Besides counteracting cardiovascular and renal dysfunction regardless of OSA, empagliflozin proved to lessen the OSA risk [136] by mitigating leptin hyperproduction and hyperactivity [137,138] and increasing adiponectin levels [138].”
Bidirectional interplay of sleep apnea syndrome and cardio-vascular disorders in diabetes
Valensi, P. E., Benmohammed, K., & Zerguine, M. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111984 · Cited by 20
The Diabetic Cardiorenal Nexus
D’Elia, J. A., Bayliss, G. P., & Weinrauch, L. A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137351 · Cited by 18
“In an exploratory analysis of the EMPA-REG Outcome trial, a cardiovascular/renal benefit has been reported in study subjects with sleep apnea [221].”
MethodObstructive sleep apnea and diabetes
Bloomgarden, Z. T. (2023) · Journal of Diabetes · doi:10.1111/1753-0407.13494 · Cited by 17
Berjaoui, C., Kibrom, B. T., Ghayyad, M. H., Joumaa, S., Labban, N. T. A., Nazir, A., Kachouh, C., Moradeyo, A. A., Wojtara, M. S., & Uwishema, O. (2023) · Health Science Reports · doi:10.1002/hsr2.1773 · Cited by 17
A Structured Narrative Review of the OSA–T2DM Axis
Passàli, D., Bellussi, L. M., Santantonio, M., & Passàli, G. C. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14124168 · Cited by 15
“A subset of studies explored novel markers (e.g., cathepsin S [30] and mitochondrial function [20]) and pharmacological agents (e.g., SGLT2 inhibitors [23,41] and metformin [20]), offering new insights into the pathophysiological mechanisms linking these two conditions.”
Chung, M., Hsu, H., Chang, C., Hung, P., Hsiao, P., Wu, L.-Y., Wu, M., Shieh, J., & Chung, C. (2022) · Scientific Reports · doi:10.1038/s41598-022-13760-7 · Cited by 14
Yen, F., Wei, J. C., Huang, Y., Hsu, T.-J., Wang, S.-T., Hwu, C., & Hsu, C.-C. (2025) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202407-703oc · Cited by 13
Butt, J. H., Jering, K., de Boer, R. A., Claggett, B. L., Desai, A. S., Hernandez, A. F., Inzucchi, S. E., Jhund, P. S., Køber, L., Kosiborod, M., et al. (2023) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2023.08.027 · Cited by 11
Self-citationThe connection between sleep deficiency and coronary artery disease: Complexities and controversies
Ujjawal, A., Lobo, T. N., Yaggi, H. K., & Neeland, I. J. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.10.002 · Cited by 13
Self-citationIshiwata, S., Kasai, T., Sato, A., Suda, S., Matsumoto, H., Shitara, J., Yatsu, S., Murata, A., Shimizu, M., Kato, T., et al. (2024) · Hypertension Research · doi:10.1038/s41440-024-01982-3 · Cited by 11
Self-citationSGLT2 inhibitors and sleep apnea; how helpful are the medications: A meta-analysis
Mir, T., Attique, H. B., Regmi, N., Sattar, Y., Sundus, S., Ambreen, S., Lohia, P., Qureshi, W., & Soubani, A. O. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2021.100084 · Cited by 12
Sevencan, B., Steenackers, N., van Laar, A. D. E., Pazmiño, S., Buyse, B., Kalkanis, A., Testelmans, D., & der Schueren, B. V. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11682 · Cited by 10
Huang, Z., Zhao, Q., Zhao, Z., THOMAS, R. J., Duan, A., Li, X., Zhang, S., Gao, L., An, C., Wang, Y., et al. (2024) · Sleep Medicine · doi:10.1016/j.sleep.2024.12.019 · Cited by 12
Duan, Y., Zhang, S., Li, Y., Zhao, W., Xie, P., Zhang, X., & Du, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.963184 · Cited by 8
“It has reported that OSA severity correlated with the amount of visceral fat than to body mass index (BMI) (Giampá et al., 2022; Neeland et al., 2020).”
BackgroundInfluentialXie, L., Song, S., Li, S., Qin, W. D., Liu, H., Zhao, C., Yu, F., & Tong, J. (2023) · Trials · doi:10.1186/s13063-023-07332-x · Cited by 9
Machine learning-based detection of sleep-disordered breathing in hypertrophic cardiomyopathy
Akita, K., Kageyama, S., Suzuki, S., Ohno, K., Kamakura, M., Nawada, R., Takanaka, C., Wakabayashi, Y., Kanda, T., Tawarahara, K., et al. (2024) · Heart · doi:10.1136/heartjnl-2023-323856 · Cited by 8
“26 The treatment of SDB in HCM has been linked to a decrease in LA size, 10 suggesting a protective effect against cardiac remodelling.”
BackgroundWhat should the recommendations be for lifestyle factors in obstructive sleep apnea?
Huang, T. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2099377 · Cited by 8
Yang, R., Zhao, Q., Guo, J., Wu, L., Qin, L., & Liu, T. (2025) · Sleep Medicine · doi:10.1016/j.sleep.2025.108708 · Cited by 6
Molecular Biomarkers and Therapeutic Approach of Patients with Diabetes and Obstructive Sleep Apnea
Elian, V., Popovici, V., Steriade, A. T., Radulian, G., Ozon, E. A., Moroșan, E., & Muşat, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010234 · Cited by 6
Sleep-disordered breathing and heart failure: a vicious cycle of cardiovascular risk
Cacciapuoti, F., D'Onofrio, A., Tarquinio, L. G., Capone, V., Mauro, C., Marfella, R., & Cacciapuoti, F. (2023) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2023.2660 · Cited by 6
“Previous research has shown a significant effect of SGLT2i in improving AHI in diabetic patients with OSA, reducing the incidence of cardiovascular and renal complications [18,19].”
BackgroundPatoulias, D., Dimosiari, A., Michailidis, T., Roditis, P., & Lampropoulos, S. (2022) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2022.06.022 · Cited by 6
Parsi, S., Sonavane, K., Ravi, U., Shirsat, P. D., Chamarthi, V. S., Gabr, M., Ponnam, H. C., Surani, S., Bansal, V., & Kashyap, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14228001 · Cited by 7
“This weight-reducing effect contributes to possible improvements in obstructive sleep apnea [34].”
Murtaza, S., Sohail, R., Akram, B., Tahira, S., Zaman, M., & Mehmood, S. N. (2025) · Journal of Sleep Research · doi:10.1111/jsr.70196 · Cited by 5
“First, SGLT-2 inhibitors promote weight loss and reduction in visceral and upper-airway adiposity, which likely reduces pharyngeal collapsibility (Kaku et al. 2014; Neeland et al. 2020; Tanriover et al. 2023).”
Monda, V. M., Porcellati, F., Strollo, F., Fucili, A., Monesi, M., Satta, E., & Gentile, S. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01791-x · Cited by 6
Empagliflozin-based quadruple oral therapy for type 2 diabetes: a prospective cohort study
Moosaie, F., Abedinzadeh, S., Rabizadeh, S., Daneshvar, K., Noorafrooz, M., Mojtahedi, F., Deravi, N., Abhari, S. M. F., Ramezani, A., Meysamie, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-024-84993-x · Cited by 4
“While previous studies have reported a significant reduction in waist circumference with empagliflozin treatment 36,37 , the results from our analysis presented a more variable trend, rather than a consistent downward trajectory.”
Zhang, X., Zhang, Y., & Hu, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1039348 · Cited by 6
“1 years, regardless of Obstructive Sleep Apnea status at baseline (71).”
BackgroundOmari, M. B., Naseri, S., & Hassan, A. J. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s448670 · Cited by 3
“81,82 A further reduction in the new onset of obstructive sleep apnea with empagliflozin treatment in diabetic patients compared to placebo has also been observed in another clinical trial.”
ResultPharmacological management of sleep apnea and obesity, a new frontier
Taweesedt, P. T., Orakpo, N., & Pelayo, R. (2025) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.11798 · Cited by 3
Diabetes mellitus, metabolic syndrome, and sleep disorders: An underestimated relationship
Patil, S. V., Tak, S., & Mirza, A. W. (2024) · Annals of Medical Science and Research · doi:10.4103/amsr.amsr_3_24 · Cited by 4
Sleep Deficiency and Opioid Use Disorder
Langstengel, J., & Yaggi, H. K. (2024) · Sleep Medicine Clinics · doi:10.1016/j.jsmc.2024.07.009 · Cited by 3
Self-citationDashek, R. J., Higashi, Y., Das, N. A., Russell, J. J., Martinez‐Lemus, L. A., Rector, R., & Chandrasekar, B. (2022) · Medical Research Archives · doi:10.18103/mra.v10i10.3237 · Cited by 2
Tao, S., Guo, S., & Tong, N. (2024) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2952 · Cited by 2
“65 These clinical studies have shown improvements in OSAS with SGLT2i (ertugliflozin, empagliflozin, and dapagliflozin) use in patients with T2DM.”
Veizi, B. G. Y., & Demircan, S. K. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112319 · Cited by 2
Diabetes and metabolic syndrome
Bruyneel, M., & Bonsignore, M. R. (2023) · European Respiratory Society eBooks · doi:10.1183/9781849841641.010822 · Cited by 2
Brikman, S., & Dori, G. (2021) · Diabetes Care · doi:10.2337/dc21-0310 · Cited by 2
Non-positive Airway Pressure Therapies for Obstructive Sleep Apnoea and Central Sleep Apnoea
Mora, J., Sunwoo, B. Y., Ramsis, M., & Malhotra, A. (2026) · Cardiac failure review · doi:10.15420/cfr.2025.24 · Cited by 1
“79 A small randomised controlled trial showed a significant decrease in AHI, improvement in SpO 2 nadir and a reduction in Epworth Sleepiness Scale scores in patients with type 2 diabetes and OSA treated with dapagliflozin, also a SGLT2 inhibitor, combined with metformin compared with those…”
Davies, M. J., Aroda, V. R., Bajaj, M. S., ElSayed, N. A., Giorgino, F., Green, J., Kalyani, R. R., Maruthur, N. M., Mathieu, C., Rosas, S. E., et al. (2026) · Diabetologia · doi:10.1007/s00125-026-06855-7 · Cited by 1
Bierer, G. B. (2022) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10324 · Cited by 1
Insuline use could increase the risk of obstructive sleep apnea in type 2 diabetes mellitusPreprint
Martorina, W. J., & Júnior, A. R. T. (2021) · Research Square · doi:10.21203/rs.3.rs-961618/v1
Sunarti, S., Indriyaningrum, N. B., Wahono, C. S., Soeatmadji, D. W., Rudijanto, A., Ratnawati, R., Karyono, S. S., & Maryunani, M. (2021) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2021.6389
“Circulating IL-6 is elevated in asthmatic patients, both active disease or intrinsic asthma [27], and also increases in allergic patients [28].”
BackgroundFarinha, J. B., Weinert, L. S., Costa, L. P., Costa, M. Z., de Peres, P. P., & Lorea, C. F. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01076-1
Sleep disordered breathing in patients with other disorders
(2023) · European Respiratory Society eBooks · doi:10.1183/9781849841641.chapter10
Long Term Airway Stability In Obstructive Sleep Apnea Patients After Maxillomandibular Advancements
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.16.028
Cardiovascular disease and sleep apnea in patients with type 2 diabetes mellitus
Koteshkova, O. M. K., Antsiferov, M. B., Antsiferova, D. M., Golubeva, Y. V. G., & Demidov, N. A. D. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-179
Integrating multidisciplinary interventions for sleep-related cardiometabolic health
Zhao, K., & Yang, S. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.079
Che cosa non sappiamo sugli SGLT-2 inibitori
Chiriacò, M., Chatzianagnostou, K., Emdin, M., & Prato, S. D. (2024) · L Endocrinologo · doi:10.1007/s40619-024-01510-y
Demko, A. (2024) · Clinical Research in Practice The Journal of Team Hippocrates · doi:10.22237/crp/1724284980
Mori, J.-I., Yamashita, K., & Aizawa, T. (2025) · Cureus · doi:10.7759/cureus.78503
“In addition, it has favorable effects on nonalcoholic fatty liver disease and sleep apnea syndrome [10,11], with additional potential multifaceted benefits still under investigation [12].”
Recent Insights into the Relationship Between Sleep Disordered Breathing and Cardiovascular Disease
Kato, M. (2025) · Yonago acta medica · doi:10.33160/yam.2025.05.001
Kusy, B., Żerańska, A., Bieńkowski, W. J., Nowakowska, M., Retman, P., Kucharczyk, P., & Charkot, J. (2025) · Romanian Journal of Neurology · doi:10.37897/rjn.2025.1.18
“Additionally, medications such as liraglutide and gliflozins, which have been studied in diabetic OSA patients, may offer cardiometabolic benefits beyond their weight-loss effects [96].”
Does glucose metabolism and its consequences depend on the phenotype of obstructive sleep apnea?
Suwannakin, A., Reutrakul, S., & Chirakalwasan, N. (2025) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000001206
Characteristics and Outcomes of IgA Nephropathy Patients With SGLT2 Inhibitor-Induced Polycythemia
Furuto, Y., Namikawa, A., Sato, D., & Shibuya, Y. (2025) · Cureus · doi:10.7759/cureus.91789
“However, no data have been reported on the changes in Ht levels after administration of SGLT2 inhibitors in this patient population [43].”
Aneni, E. C., Karim, I., Rutter, J., Olaseni, O., Kreinin, I., Tsang, S. W., Wang, Z., Strohl, K. P., Yaggi, H. K., & Neeland, I. J. (2025) · Contemporary Clinical Trials · doi:10.1016/j.cct.2025.108134
Self-citationObstructive sleep apnoea is associated with accelerated progression of diabetic kidney disease
Nielsen, S., Thomsen, M. B., Nyvad, J. T., Laugesen, E., Grove, E. L., Poulsen, P. L., Christensen, K. L., Sørensen, M. V., Berg, P., & Buus, N. H. (2026) · Diabetic Medicine · doi:10.1111/dme.70340
Syndrome d’apnées obstructives du sommeil et diabète : une forte relation maintenant modifiable
Valensi, P. E., & Benmohammed, K. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.06.003
Aladhab, R. A. (2026) · International Journal of Basic & Clinical Pharmacology · doi:10.18203/2319-2003.ijbcp20262782
Anti-obesity medications for the management of obstructive sleep apnoea
Collings, T., & Outhoff, K. (2026) · SA pharmaceutical journal. · doi:10.36303/sapj.4699
Benmohammed, K., & Valensi, P. E. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.09.007
Apnées obstructives du sommeil et complications cardiovasculaires chez les patients diabétiques
Valensi, P. E., & Benmohammed, K. (2026) · Médecine des Maladies Métaboliques · doi:10.1016/j.mmm.2026.09.006
Qiaoliang, D., Tai, H., Shen, Y., & Zhang, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-11042412/v1
Polecka, A., Cwalina, U., & Olszewska, E. (2026) · Antioxidants · doi:10.3390/antiox15111369
Metadata
- Authors
- Neeland, I. J., Eliasson, B., Kasai, T., Marx, N., Zinman, B., Inzucchi, S. E., Wanner, C., Zwiener, I., Wojeck, B. S., Yaggi, H. K., & Johansen, O. E.
- Affiliations
- Case Western Reserve University (US)
- Department of Medicine, University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
- Juntendo University (JP)
- Universitätsklinikum Aachen (DE)
- Mount Sinai Hospital (CA)
- Yale University (US)
- Universitätsklinikum Würzburg (DE)
- Boehringer Ingelheim (Germany) (DE)
- Boehringer Ingelheim (Norway) (NO)
- Corresponding author
- Neeland, Ian J.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-10-01
- Volume
- 43
- Issue
- 12
- Pages
- 3007-3015
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7770278
- OpenAlex
- W3091412683
- Cited by
- 93
- References
- 38
- Citations by year
- 2026: 10 · 2025: 19 · 2024: 19 · 2023: 13 · 2022: 24 · 2021: 8
- FWCI
- 8.49
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boehringer Ingelheim
- Eli Lilly and Company
- National Institute of Diabetes and Digestive and Kidney Diseases (K23-DK-106520)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Physiology (medical) › Obstructive Sleep Apnea Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- empagliflozin, obstructive sleep apnea, EMPA-REG OUTCOME trial, type 2 diabetes, cardiovascular outcomes, renal outcomes, heart failure hospitalization, kidney disease, obesity, SGLT2 inhibitors, major adverse cardiovascular events
- MeSH terms
- Aged, Benzhydryl Compounds, Cardiovascular Diseases, Cardiovascular System, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Glucosides, Humans, Kidney Diseases, Male, Middle Aged, Risk Factors, Sleep, Comorbidity, Incidence, Prevalence, Treatment Outcome, Sleep Apnea, Obstructive
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.